There are currently 97 active clinical trials seeking participants for Type 2 Diabetes research studies. The states with the highest number of trials for Type 2 Diabetes participants are California, Texas, Florida and North Carolina.
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475
Recruiting
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/01/2025
Locations: Helios Clinical Research - Phoenix, Phoenix, Arizona +55 locations
Conditions: Type 2 Diabetes
Register for Updates
Ultrasound Effects on Glycemic Control in T2DM
NCT05354947
Recruiting
This is an open label, exploratory pilot study that will assess the effects of dual site focused pulsed ultrasound treatment on glycemic parameters in subjects with T2DM.
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
06/30/2025
Locations: Yale-New Haven Hospital, New Haven, Connecticut
Conditions: Type 2 Diabetes
Register for Updates
Extracellular Vesicles, Insulin Action, and Exercise
NCT06546085
Recruiting
Extracellular vesicles (EVs) play a role in obesity-induced insulin resistance and likely impact the development of cardiovascular disease. However, little is known on how EVs affect vascular insulin action in people. The purpose of this study is to understand how EVs play a role in type 2 diabetes related cardiovascular disease. This research will also study if exercise can change how EVs impact blood flow and metabolic health. This study will contribute to designing precision medicine to treat... Read More
Gender:
ALL
Ages:
Between 30 years and 80 years
Trial Updated:
06/30/2025
Locations: Institute for Food, Nutrition, and Health, New Brunswick, New Jersey +2 locations
Conditions: Type 2 Diabetes, Obesity
Register for Updates
SGLTi, Hepatic Glucose Production and Ketogenesis
NCT05960656
Recruiting
In this study, we will test the hypothesis that distinct mechanisms account for the SGLT2i-induced stimulation of ketogenesis and lipolysis versus endogenous (hepatic) glucose production in patients with type 2 diabetes (T2D) and type 1 diabetes (T1D), and that the increases in ketone production and lipolysis can be prevented by concomitant administration of the thiazolidinedione pioglitazone. We will conduct five distinct experiments to test this hypothesis in patients with T2D and T1D. MAIN S... Read More
Gender:
ALL
Ages:
Between 30 years and 75 years
Trial Updated:
06/26/2025
Locations: Texas Diabetes Institute/UH, San Antonio, Texas
Conditions: Type 2 Diabetes
Register for Updates
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
NCT06739122
Recruiting
The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
06/24/2025
Locations: University of Arizona, Tucson, Arizona +29 locations
Conditions: Type 2 Diabetes
Register for Updates
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
NCT06297603
Recruiting
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Nephrology Consultants, Huntsville, Alabama +78 locations
Conditions: Type 2 Diabetes
Register for Updates
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792
Recruiting
The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson, Arizona +88 locations
Conditions: Obesity, Overweight, Type 2 Diabetes
Register for Updates
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472
Recruiting
The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO. Participation in the study will last about 18 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson, Arizona +88 locations
Conditions: Obesity, Overweight, Type 2 Diabetes
Register for Updates
Youth-Onset Type 2 Diabetes and Heart Disease: The Young at Heart Prospective Cohort Study
NCT06730113
Recruiting
Background: Type 2 diabetes is a disease that affects blood sugar levels. Complications can include heart and blood vessel (vascular) diseases. Rates of type 2 diabetes have tripled in children and young adults over the last 40 years. Vascular diseases are also increasing in young people. Objective: To learn more about factors, including type 2 diabetes, that may cause vascular disease in young people. Eligibility: People aged 12 to 25 years who (1) have type 2 diabetes; (2) are overweight... Read More
Gender:
ALL
Ages:
Between 12 years and 25 years
Trial Updated:
06/18/2025
Locations: Children's National Hospital (CNH), Washington, District of Columbia +1 locations
Conditions: Obesity, Type 2 Diabetes
Register for Updates
Time Limited Eating in Adolescents With Type 2 Diabetes (KT2D)
NCT04536480
Recruiting
To find the effectiveness of a diet plan (Time Limited Eating or TLE) on glycemic control, B-cell function, body fat, and body mass index (BMI) in adolescents with type 2 diabetes.
Gender:
ALL
Ages:
Between 12 years and 21 years
Trial Updated:
06/18/2025
Locations: Children's Hospital of Los Angeles, Los Angeles, California
Conditions: Pediatric Obesity, Type 2 Diabetes, Time Restricted Eating
Register for Updates
Ketogenic Diet and Diabetes Demonstration Project
NCT06115265
Recruiting
KDDP is a prospective, 12-month pilot study comparing the effects of a novel lifestyle program, the Ketogenic Diet and Diabetes Demonstration Project (KDDP) to those of the National Diabetes Prevention Program (NDDP). KDDP is modeled to mimic the delivery platform of NDPP with the exception that participants in KDDP will be placed on a medically-supervised ketogenic diet, and participants in NDPP will be placed on a low fat diet. The purpose of this study is to compare the metabolic effects of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: University of New Mexico, Albuquerque, New Mexico
Conditions: Type 2 Diabetes, PreDiabetes, Obesity, Ketogenic Dieting
Register for Updates
Enhancing Telemedicine for T2D
NCT06740435
Recruiting
The goal of this pilot clinical trial is to assess feasibility of an intervention to deliver comprehensive, high-quality diabetes care through telemedicine among adults with type 2 diabetes who use insulin and have multiple chronic health conditions. The main question it aims to answer is: Is an enhanced telemedicine intervention for type 2 diabetes compared to usual telemedicine care feasible? Researchers will compare the enhanced telemedicine intervention to usual telemedicine care to see if... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/16/2025
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Type 2 Diabetes
Register for Updates